docetaxel teva pharma
teva pharma b.v. - docetaxel - carcinoma, non-small-cell lung; breast neoplasms; prostatic neoplasms - antineoplastic agents - breast cancerdocetaxel teva pharma monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.non-small-cell lung cancerdocetaxel teva pharma is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.docetaxel teva pharma in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel teva pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.
3a-cef 10 dt
3a pharma. - cefuroxime - dt - 500mg - 10
3a-cef alu 10 dt
3a pharma. - cefuroxime - dt - 250mg - 10
3a-cef alu 10 dt
3a pharma. - cefuroxime - dt - 500mg - 10
3a-ceo alu alu 10 cap
3a pharma. - lycopene - cap - 10
3a-fer alu-alu 10 cap
3a pharma. - carbonyl iron,vit.b12,vit.c,folic acid,zinc sulph. - cap - 100mg,15mcg,150mg,1mg,61.8mg - 10
3a-gat 10 tab
3a pharma. - gatifloxacin - tab - 400mg - 10
3a-gat alu-alu 10
3a pharma. - gatifloxacin - 400mg - 10
3a-sul vial inj
3a pharma. - cefotaxime,sulbactam - inj - 1g,500;mg - vial
3a-taz vial inj
3a pharma. - ceftazidime - inj - 1000mg - vial